Beijing Luzhu Biotechnology Co., Ltd. (Stock code: 2480) has been successfully listed on the Main board of the HKEX on 8 May 2023, the maximum fund raising size is HK$432M.

Beijing Luzhu Biotechnology Co Ltd is a China-based company principally engaged in drug discovery, research and development and commercialization. The Company is also engaged in out-licensing human vaccines and therapeutic biologics. Its products under clinical development include recombinant herpes zoster vaccine LZ901, and antibody injection products K3 and K193. Its LZ901 is mainly used to prevent herpes zoster caused by varicella zoster virus in adults aged 50 and above. The Company operates in the domestic market and overseas markets. 

CBI is honoured to be engaged in providing Due Diligence service with regards to this listing application.